1. Home
  2. MWH vs IMVT Comparison

MWH vs IMVT Comparison

Compare MWH & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MWH

SOLV Energy Inc. Class A Common Stock

N/A

Current Price

$28.92

Market Cap

5.9B

Sector

Industrials

ML Signal

N/A

Logo Immunovant Inc.

IMVT

Immunovant Inc.

HOLD

Current Price

$24.02

Market Cap

5.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MWH
IMVT
Founded
2008
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Military/Government/Technical
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.9B
5.0B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
MWH
IMVT
Price
$28.92
$24.02
Analyst Decision
Strong Buy
Buy
Analyst Count
10
9
Target Price
$35.10
$30.78
AVG Volume (30 Days)
658.9K
997.2K
Earning Date
03-19-2026
02-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$51.54
N/A
Revenue Next Year
$14.28
N/A
P/E Ratio
$50.60
N/A
Revenue Growth
N/A
N/A
52 Week Low
$26.60
$12.72
52 Week High
$33.00
$29.25

Technical Indicators

Market Signals
Indicator
MWH
IMVT
Relative Strength Index (RSI) 46.51 42.84
Support Level $27.24 $22.00
Resistance Level $30.66 $24.63
Average True Range (ATR) 1.60 1.16
MACD 0.07 -0.04
Stochastic Oscillator 43.29 32.41

Price Performance

Historical Comparison
MWH
IMVT

About MWH SOLV Energy Inc. Class A Common Stock

SOLV Energy Inc is a provider of infrastructure services to the power industry, including engineering, procurement, construction, testing, commissioning, operations, maintenance and repowering. It specializes in designing, building and maintaining utility-scale solar and battery storage projects and related T&D infrastructure. The company's projects include: The Eldorado Solar Project, Gravel Pit Solar Project, and Vikings Solar-plus-Storage Project. It operates in one reportable segment which derives revenue through providing EPC, O&M and Development services throughout the Unites Sates. The company derives maximum of revenue from its EPC contracts.

About IMVT Immunovant Inc.

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.

Share on Social Networks: